Covid 19 Research using Clinical Trials (Home Page)
no interventionWiki
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (2)
Correlated MeSH Terms (2)
|
Name (Synonyms) |
Correlation |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.07 |
D018352 | Coronavirus Infections NIH | 0.06 |
Correlated HPO Terms (0)
|
Name (Synonyms) |
Correlation |
There is one clinical trial.
Clinical Trials
COVID19 pandemic currently represents a public health emergency. Based on current data, 15%
of the affected individuals will develop a severe form of the disease requiring admission to
hospital and respiratory support. Data show that age and cardiovascular pre-existing
comorbidities predict a poorer outcome. Some evidence suggests that a subset of patients with
poorer outcome present with a cytokine mediated inflammatory response and with a secondary
HLH like clinical phenotype. No data are so far available with regard to the risk of severe
COVID19 disease in the post stem cell transplantation setting. Recipients of allogeneic stem
cell transplantation are by definition immunologically dysregulated and could potentially
present with a unique immune-inflammatory response to COVID 19 infection. Moreover, the
immunosuppression used to prevent/treat GVHD may also impact clinical progression and it is
possible that because of their immunological defects, SCT patients could potentially have
prolonged carriage of the virus and hence act as "super spreaders".
The present study aims at documenting clinical and biological characteristics, including
immunological profiling, of allogeneic stem cell transplant recipients presenting with severe
COVID 19 infection and its impact on patients survival. This work may provide the scientific
basis for targeted therapy with biological agents in this patient group.
NCT04349540 COVID19 Other: no intervention
Primary Outcomes
Measure: Comparison of inflammatory/immunological biomarkers <72 hours after development of oxygen requirement Time: 72 hrs
Secondary Outcomes
Measure: Overall survival at 30 and 100 days after development of oxygen requirement Time: day +30 and +100
Measure: Comparison of 30 and 100 day survival in SCT patients who are vs are not ongoing immunosuppression Time: Day +30 and +100
Measure: Proportion of patients requiring mechanical ventilation Time: Day +30
Measure: Incidence of secondary HLH (as defined by HS score) Time: Day +30
No related HPO nodes (Using clinical trials)